Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, is a newly developed oral antidiabetic drug to enhance renal glucose excretion or glycosuria and reduce hyperglycaemia in an insulin-independent manner by highly selective inhibition of SGLT2 [12]. Here, SLC5A2 is linked to Hyperglycemia.